Side-by-side · Research reference

DSIPvsRetatrutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BPhase 2Reviewed10/41 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

01Mechanism of Action

Parameter

DSIP

Retatrutide

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Feedback intact?

—

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Antibody development

—

02Dosage Protocols

Parameter

DSIP

Retatrutide

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

Frequency

Once daily, pre-sleep

Once weekly

Lower / starter dose

50 mcg pre-sleep

—

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Duration

8–12 weeks per cycle

Indefinite for chronic indication (presumed)

Reconstitution

Bacteriostatic water

Investigational; not commercially available

Timing

30–60 min pre-sleep

Any time of day

Half-life

Short plasma; CNS effects last hours

~6 days (estimated from class)

Titration schedule

—

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

04Side Effects & Safety

Parameter

DSIP

Retatrutide

Injection site reaction

Mild irritation

—

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

Avoid (insufficient data)

GI symptoms

—

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

Heart rate

—

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

Glucose handling

—

Glycemic improvement; rare hyperglycemia from glucagon component

Pancreatitis risk

—

Class warning

Thyroid C-cell tumours

—

Class warning (presumed)

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

05Administration Protocol

Parameter

DSIP

Retatrutide

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

2. Injection site

SQ — abdomen. Rotate sites.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

30–60 min pre-sleep.

Once weekly, same day.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Refrigerate 2–8 °C. Light-protected.

5. Needle

29–31G insulin syringe.

27–31G, 4–8 mm insulin syringe.